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Abstract
Patients with atrial fibrillation who undergo a coronary intervention are eligible for both anticoagulation and (dual) an-
tiplatelet therapy ((D)APT). An optimal balance has to be found to reduce the thromboembolic risk (i.e. stroke, systemic
embolism and myocardial infarction) and to minimise the increased risk of bleeding with concomitant use of an antico-
agulant and (D)APT. Owing to a lack of evidence, the guideline recommendations are predominantly based on expert
opinion. Current evidence indicates that the combination of a non-vitamin K oral anticoagulant (NOAC) and clopidogrel is
safer than vitamin-K oral antagonists plus DAPT, which increases the risk of bleeding, without clear advantages in regard
to efficacy. Concerning whether (N)OACs should be combined with single APT rather than DAPT, the findings of the
WOEST, PIONEER AF-PCI and RE-DUAL PCI trials seem to favour a combination with clopidogrel only, thus omitting
aspirin. Choosing the optimal treatment strategies for individual patients on NOACs and (D)APT will remain a challenge
for clinicians, though triple therapy seems to be the less favourable option owing to the increased risk of bleeding.
Keywords Anticoagulation · Antiplatelet therapy · Atrial fibrillation · Acute coronary syndrome · Coronary intervention
Introduction
Almost 30% of patients with atrial fibrillation (AF) have
co-existing coronary artery disease (CAD) [1, 2]. Antico-
agulants are prescribed to AF patients to reduce the risk of
stroke or systemic embolism. However, there is still a risk
of the patient developing acute coronary syndrome (ACS),
requiring percutaneous coronary intervention (PCI). Fol-
lowing PCI, antiplatelet drugs such as aspirin and P2Y12
inhibitors (clopidogrel, prasugrel and ticagrelor) play a pre-
dominant role in the prevention of in-stent thrombosis and
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cardiovascular events [3]. Antiplatelet therapy (APT) alone
is inferior to oral anticoagulation for reducing the risk of
thromboembolic events in AF patients [4]. According to the
present European Society of Cardiology (ESC) guidelines,
AF patients with co-existing ACS and those who undergo
a coronary intervention are eligible for both anticoagulation
and (dual) antiplatelet therapy ((D)APT) [5, 6]. However,
a combination of warfarin with (D)APT carries a more than
threefold higher risk for non-fatal and fatal bleeding com-
pared with warfarin monotherapy [7]. An optimal balance
has to be found to reduce the thromboembolic risk (i.e.
stroke, systemic embolism and myocardial infarction) and
to minimise the increased risk of bleeding resulting from
concomitant use of an anticoagulant and (D)APT. Owing to
the lack of evidence, the 2016 ESC guideline on the treat-
ment of ACS in AF patients and the 2017 ESC focused
update on DAPT in CAD are predominantly based on ex-
pert opinion [3, 6, 8]. This review summarises and discusses
the most recent key developments and future studies with
regard to combining anticoagulation (non-vitamin K oral
anticoagulants (NOACs) or vitamin K antagonists (VKA))
with APT in AF patients undergoing PCI.
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Single antiplatelet therapy with clopidogrel only, thus omitting aspirin, in combination with oral 
anticoagulation is safer than dual antiplatelet therapy in atrial fibrillation (AF) patients who 
undergo a coronary intervention. Therefore, triple antithrombotic therapy seems to be too much.
The lowest dose of the non-vitamin K oral antagonist suitable for stroke prevention in AF 
patients should be used in combination with antiplatelet therapy. Dose adjustments, or even 
withholding anticoagulation, should not be decided solely on the basis of the bleeding risk.
All ongoing trials on NOACs in combination with antiplatelet therapy are primarily focused on 
the safety endpoint in terms of major bleeding or clinically relevant non-major bleeding. The 





Guideline recommendations and current
practice
The 2014 AF guideline for the management of AF patients
of the American College of Cardiology/American Heart As-
sociation Task Force on Practice Guidelines and the Heart
Rhythm Society (AHA/ACC/HRS) recommends warfarin
rather than NOACs as the first-choice therapy in AF pa-
tients with ACS. This guideline mentions considering dual
therapy consisting of an OAC plus clopidogrel 75mg once
daily (q.d.) as an alternative to initial triple therapy [5].
The 2015 ESC non-ST segment elevation myocardial in-
farction (NSTEMI) guideline recommends that the use of
prasugrel or ticagrelor as a part of triple therapy should be
avoided in the absence of safety and efficacy data (class C
recommendation) [3]. Because it is known that the addition
of (D)APT to oral coagulation increases the bleeding risk,
limited data suggest that clopidogrel is probably the safest
of the available P2Y12 inhibitors because of its lowest
bleeding risk [9]. If the OAC is a VKA, the ESC NSTEMI
guideline recommends a target international normalisation
ratio (INR) of 2.0–2.5 with the exception of patients with
a mechanical prosthetic valve in the mitral position [3].
The 2016 ESC guideline for AF recommends a short
period of triple therapy (OAC+ aspirin+ clopidogrel) fol-
lowed by a period of dual therapy (OAC+ APT, preferably
up to 12 months after the event) in AF patients with co-ex-
isting ACS and those who undergo PCI [6]. The duration of
the dual and triple therapy depends on the bleeding risk as
calculated by the HAS-BLED score, the reason for the PCI
(ACS or stable CAD) and the type of stent (bare-metal ver-
sus drug-eluting). Modifiable bleeding risk factors should
be corrected to minimise the risk of bleeding. This guideline
also mentions dual therapy with an OAC and clopidogrel as
an emerging alternative to triple therapy based on the results
of the WOEST study (What is the Optimal antiplatElet and
anticoagulant therapy in patients with oral anticoagulation
and coronary StenTing) [10] When a NOAC is preferred
for anticoagulation, the lowest effective dose for stroke pre-
vention should be used (apixaban 5mg twice daily (b.i.d.),
dabigatran 110mg b.i.d., edoxaban 60mg q.d., rivaroxaban
20mg q.d.) or the appropriate reduced dose if indicated by
dose-reduction criteria according to the drug labelling [2].
Fairly recently, a new ESC focused update was published
on DAPT in CAD [8]. The guideline expresses a prefer-
ence for clopidogrel as a part of triple antithrombotic ther-
apy; prasugrel and ticagrelor should be avoided in com-
bination with oral anticoagulation because of worrisome
bleeding rates in registries (level C recommendation). In
patients treated with a NOAC, the lowest effective dose for
stroke prevention is also recommended in this guideline.
Interestingly, the most innovative recommendation in this
guideline is the use of rivaroxaban 15mg q.d. as an alterna-
tive to rivaroxaban 20mg q.d. when combined with aspirin
and/or clopidogrel. The new guideline seems to base this
level B recommendation on the results of the PIONEER
AF-PCI (Open-Label, Randomized, Controlled, Multicen-
ter Study Exploring Two Treatment Strategies of Rivaroxa-
ban and a Dose-Adjusted Oral Vitamin K Antagonist Treat-
ment Strategy in Subjects with Atrial Fibrillation who Un-
dergo Percutaneous Coronary Intervention) study. It is note-
worthy that this same guideline states that the PIONEER
AF-PCI study is largely underpowered for the assessment
of meaningful differences in the incidence of relevant is-
chaemic events, such as stent thrombosis or stroke rates.
Dual therapy with clopidogrel 75mg and oral anticoagula-
tion is still recommended for consideration as an alternative
to 1 month of triple therapy for patients in whom the bleed-
ing risk outweighs the ischaemic risk [8].
The European Heart Rhythm Association conducted
a survey in 2014 to provide an insight into current prac-
tice in Europe regarding the management of AF patients
presenting with ACS. This survey showed that, in 91.1%
of cases, combining warfarin with aspirin and clopidogrel
was preferable in AF patients after PCI [11]. Most of
the responding centres treated patients with triple therapy
(OAC+ aspirin+ clopidogrel) for 3 months followed by
12 months of dual therapy (OAC+ aspirin), and the ma-
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jority used warfarin [11, 12]. Of the NOACs, rivaroxaban
15mg o.d. and apixaban 2.5mg b.i.d. were most frequently
used.
Triple vs dual antithrombotic therapy
Post hoc analyses
In the post hoc analysis of the RE-LY (Randomized Evalu-
ation of Long-Term Anticoagulation Therapy) trial, dabiga-
tran 110mg b.i.d. plus (D)APT was not inferior to warfarin
plus (D)APT in reducing stroke and systemic embolism
and was associated with fewer major bleeds. There was an
additive effect on major bleeding risk with the number of
antiplatelet drugs used regardless of the OAC dose used,
but (D)APT did not reduce the risk of thromboembolism
or stroke [13]. A subanalysis of the ENGAGE AF-TIMI 48
(Effective Anticoagulation with Factor Xa Next Generation
in Atrial Fibrillation—Thrombolysis in Myocardial Infarc-
tion 48) trial also looked at the combination of a NOAC
plus APT [14]. Concomitant use of edoxaban 60mg q.d. or
30mg q.d. plus APT was compared with warfarin plus APT
in AF patients. The study showed that combining APT with
edoxaban or warfarin increased the bleeding risk. There was
less major bleeding in patients that used edoxaban than in
those using warfarin. Moreover, APT did not influence the
efficacy of edoxaban compared to warfarin in preventing
stroke or systemic embolic events. A predefined analysis of
the ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation) trial
assessed the effect of concomitant aspirin use on the effi-
cacy and safety of apixaban compared with warfarin in AF
patients [15]. Apixaban use resulted in similar reductions
in stroke and systemic embolism among aspirin users and
non-users, compared with warfarin. Apixaban had a con-
sistent effect among aspirin users and non-users on stroke
or systemic embolism, ischaemic stroke, myocardial infarc-
tion, and death both in the overall population and among the
subgroups of patients with and without a history of arterial
vascular disease. There were statistically significant reduc-
tions in major bleeding for aspirin combined with apixaban
compared to warfarin plus aspirin. The effect of apixaban
in causing less major bleeding, haemorrhagic stroke, major
or clinically relevant non-major bleeding and any bleeding
was comparable in subgroups with and without a history
of arterial vascular disease. Only 0.7% of the total popula-
tion of the ARISTOTLE trial underwent triple therapy (as-
pirin+ P2Y12 receptor antagonist+ study drug) for at least
7 days. There was no subanalysis for AF patients with ACS
or patients who underwent PCI.
Results of (N)OACs combined with (D) APT in AF
patients
The WOEST study compared the safety of triple therapy
(VKA (target INR 2.0) with clopidogrel and aspirin) with
that of dual therapy (VKA with clopidogrel) in patients that
used an OAC and underwent PCI. This study showed that
omitting aspirin significantly reduced bleeding complica-
tions (hazard ratio (HR) 0.36, 95% confidence interval (CI)
0.26–0.50, p< 0.0001) and was associated with a lower risk
of the combined secondary endpoint consisting of death,
myocardial infarction, stroke, target-vessel revascularisa-
tion and stent thrombosis (HR 0.60, 95% CI 0.38–0.94)
[10]. It should be noted that the WOEST study was not
powered to detect differences in the occurrence of throm-
botic events when aspirin was omitted.
The PIONEER AF-PCI trial [16] compared two differ-
ent rivaroxaban treatment strategies with a VKA treatment
strategy in patients with AF undergoing PCI. The drug
regimens were based on the results of the ATLAS ACS
2-TIMI 51 study (Anti-Xa Therapy to Lower Cardiovas-
cular Events in Addition to Standard Therapy in Subjects
with Acute Coronary Syndrome-Thrombolysis in Myocar-
dial Infarction 51) and the results of the WOEST study.
The PIONEER AF-PCI included the more potent P2Y12 in-
hibitors ticagrelor and prasugrel as a treatment option, with
the choice of the P2Y12 inhibitor at the discretion of the
physician. However, over 93% of the patients were treated
with clopidogrel, and therefore no statements per type of
P2Y12 inhibitor can be made. The PIONEER trial re-
sults demonstrated that use of rivaroxaban 15mg q.d. plus
a P2Y12 inhibitor for 12 months and rivaroxaban 2.5mg
b.i.d. plus DAPT for 1, 6 or 12 months was associated
with lower rates of clinically significant bleeding com-
pared to VKA plus DAPT for 1, 6 or 12 months (16.8%
for rivaroxaban 15mg q.d. plus P2Y12 inhibitor, 18.0%
for rivaroxaban 2.5mg b.i.d. plus DAPT, 26.7% for VKA
plus DAPT; HR= 0.59, 95% CI= 0.47–0.76 for rivarox-
aban 15mg q.d. plus P2Y12 inhibitor vs VKA+ DAPT
and HR= 0.63, 95% CI= 0.50–0.80 for rivaroxaban 2.5mg
b.i.d. plus DAPT vs VKA+ DAPT). The rates of the pre-
specified endpoint death from cardiovascular causes, my-
ocardial infarction or stroke were similar in the three groups
[16]. Notably, although the stroke rate was not different
in the three groups, the study was underpowered to draw
any conclusion about the effect on stroke prevention, and
the 2.5mg dose of rivaroxaban was not tested for stroke
prevention in AF. The post hoc analysis of the PIONEER
AF-PCI trial demonstrated that AF patients who underwent
PCI and were treated with rivaroxaban 15mg q.d. plus
a P2Y12 inhibitor for 12 months or rivaroxaban 2.5mg
b.i.d. plus DAPT for 1, 6 or 12 months had a lower risk of
all-cause mortality or recurrent hospitalisation for adverse
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events compared to those with VKA plus DAPT for 1, 6 or
12 months [17].
The RE-DUAL PCI trial (Randomized Evaluation of
Dual Therapy with Dabigatran vs Triple Therapy with War-
farin in Patients with Atrial Fibrillation That Undergo a Per-
cutaneous Coronary Intervention with Stenting) compared
dual therapy consisting of dabigatran (110mg and 150mg
b.i.d.) and clopidogrel or ticagrelor with triple therapy con-
sisting of warfarin, aspirin and clopidogrel or ticagrelor in
patients with non-valvular atrial fibrillation that underwent
a PCI with stenting [18]. In this trial, no distinction is made
between the specific P2Y12 inhibitors and the duration of
(D)APT treatment, and only 12% received ticagrelor. The
average age of the patients was 70.8 years, and ACS was
the most frequent PCI indication (50.5%). The incidence of
major or clinically relevant non-major bleeding events dur-
ing follow-up was significantly lower for dabigatran plus
P2Y12 than for triple therapy (HR 0.52, 95% CI 0.42–0.63
for dabigatran 110mg and HR 0.72, 95% CI 0.58–0.88 for
dabigatran 150mg). The two dual-therapy groups were not
inferior with respect to the incidence of the composite effi-
cacy endpoint (myocardial infarction, stroke, systemic em-
bolism, death or unplanned revascularisation) as compared
with the triple-therapy group. In contrast to the PIONEER
AF-PCI trial, the NOAC doses in the RE-DUAL PCI trial
(dabigatran 150 and 110mg b.i.d.) have both been proved
to be effective for stroke prevention in AF. Unfortunately,
as only a small number of patients were enrolled per dabi-
gatran dose group, the trial was not powered to examine the
efficacy according to dose. Also, the trial was not powered
to allow for comparisons of individual components of the
efficacy endpoint.
Overall, the results from the WOEST, PIONEER AF-PCI
and the RE-DUAL PCI trials suggest that in AF patients
who recently underwent PCI, dual therapy with a com-
bination of (N)OAC and clopidogrel is safer than triple
therapy with OAC plus aspirin and clopidogrel. The post
hoc analysis of the RE-LY study demonstrated that dabiga-
tran 110mg b.i.d. plus DAPT (aspirin and clopidogrel) is
safer than VKA plus DAPT in terms of bleeding. Whether
this is also true for dabigatran plus clopidogrel versus VKA
plus clopidogrel cannot be concluded from the study results
published thus far. It should be noted that the RE-DUAL
and PIONEER AF-PCI studies as well as the post-analyses
of previous studies had a target INR of 2.0–3.0, which is
higher than the guideline recommendation of 2.0–2.5. The
time in therapeutic range (TTR) is a very import aspect
to take into account, since a low TTR could influence the
clinical outcomes.
Ongoing trials
A summary of the multiple ongoing trials evaluating the role
of NOACs and (D)APT in AF patients with co-existing ACS
is presented in Tab. 1. The AUGUSTUS trial (an Open-
label, 2× 2 Factorial, Randomized Controlled, Clinical Trial
to Evaluate the Safety of Apixaban vs Vitamin K Antago-
nist and Aspirin vs Aspirin Placebo in Patients with Atrial
Fibrillation and Acute Coronary Syndrome or Percutaneous
Coronary Intervention; NTC02415400) compares the safety
of apixaban 5mg (or 2.5mg) b.i.d. with VKA both with and
without aspirin in patients with AF and ACS or PCI. All
patients in this study will also be taking a P2Y12 inhibitor.
Because of its 2× 2 factorial design, this study will provide
insight into the safety of apixaban versus a VKA when
both are combined with single APT. Moreover, it will ad-
dress the safety and efficacy of triple versus dual therapy
in a randomised design: OAC (VKA/NOAC) with DAPT
versus OAC (VKA/NOAC) with single APT. The safety
and efficacy of edoxaban in AF patients who undergo PCI
with stenting will be investigated in the ENTRUST-AF-
PCI trial (Edoxaban Treatment Versus Vitamin K Antago-
nist in Patients with Atrial Fibrillation Undergoing Percu-
taneous Coronary Intervention; NTC02866175). This study
will compare the safety and efficacy of 60mg or 30mg
edoxaban plus clopidogrel or another P2Y12 inhibitor with
a VKA plus clopidogrel and 1–12 months of aspirin (in
the presence of a documented clinical need: prasugrel or
ticagrelor) [19]. The ongoing trial investigating rivaroxaban
in combination with APT in AF patients with ACS is the
RT-AF trial (Rivaroxaban in Patients with Atrial Fibrilla-
tion and Coronary Artery Disease Undergoing Percutaneous
Coronary Intervention; NTC02334254). The RT-AF trial
evaluates the safety of rivaroxaban 2.5mg b.i.d. plus tica-
grelor versus triple therapy with warfarin plus clopidogrel
and aspirin [20]. Safety is assessed based on a composite
primary endpoint of major bleeding and clinically relevant
non-major bleeding. The last ongoing trial which will pro-
vide information about the management of NOACs in AF
patients with ACS is the WOEST 2 registry (NTC0263520).
This study is a prospective, international registry on con-
comitant use of OACs and P2Y12 inhibitors in patients with
AF or heart valve prosthesis undergoing coronary revascu-
larisation. This study will provide insight into the efficacy
and safety of all possible combinations of NOACs and an-
tiplatelet inhibitors.
Most of the treatment arms of the ongoing trials focus
on one single NOAC combined with a single antiplatelet
drug. Based on the design of the trials, superiority or
even non-inferiority of combining a single antiplatelet drug
with a NOAC compared to DAPT plus a NOAC cannot
be demonstrated, with the exception of the AUGUSTUS
trial, where apixaban plus clopidogrel plus aspirin will be
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Table 1 Overview of ongoing trials on concomitant use of non-vitamin K oral anticoagulants and antiplatelet drugs in atrial fibrillation patients
with an acute coronary syndrome
Trial AUGUSTUS ENTRUST-AF-PCI RT-AF WOEST 2 registry










Objective To assess the safety of the
different treatment arms in AF
patients undergoing PCI
To assess the safety of the
different treatment arms
in AF patients undergoing
PCI
To assess the safety of the
different treatment arms
in AF patients undergoing
PCI
To assess the different man-
agement patterns and safety
and efficacy outcomes of
combined use of OAC and
a P2Y12 inhibitor in patients
with AF and/or a heart valve
prosthesis undergoing PCI
Pt number 4,600 1,500 420 2,200
Follow-up 6 months 24 months 12 months 24 months
Estimated
completion
December 2018 February 2019 January 2016 December 2019
Arms Apixaban 5mg (or 2.5mg
according to dose reduction
criteria) b.i.d. + P2Y12 in-
hibitor+ ASA 81mg q.d.
Edoxaban 60mg q.d. (or
edoxaban 30mg q.d ac-




b.i.d. + ticagrelor 90mg
b.i.d. Antiplatelet therapy
is mandatory at least
1 month after BMS
implantation, and
6 months after DES
implantation
All combinations of chronic
OAC and a P2Y12 inhibitor
with or without ASA
Apixaban 5mg (or
2.5mg) b.i.d. + P2Y12 in-
hibitor+ Placebo
VKA + clopidogrel 75mg
q.d. + ASA 100mg
30 days to 12 months
VKA + P2Y12 inhibitor+ ASA
81mg q.d.
In case of a documented
clinical need: prasugrel [5
or 10mg q.d.] or ticagrelor
[90mg b.i.d.]
Rivaroxaban 2.5mg/5mg
b.i.d. + ticagrelor 90mg
b.i.d. Antiplatelet therapy
is mandatory at least 1
month after BMS
implantation, and
6 months after DES
implantation




Time to ISTH major or
CRNM bleeding during the
treatment period
Number of major or
CRNM ISTH-bleeding
Number of major or
CRNM bleeding
Composite of thrombotic
events (MI, stroke, TIA, SE)
and cardiovascular death and
Bleeding events
AF atrial fibrillation, ASA aspirin, b.i.d. twice daily, BMS bare metal stent, CRNM Clinically Relevant Non-Major, DES drug-eluting stent, INR in-
ternational normalized ratio, ISTH International Society on Thrombosis and Hemostasis, MI myocardial infarction, NVAF, OAC oral anticoagulant,
q.d. once daily, PCI percutaneous coronary intervention, SE systemic embolism; TIA transient ischemic attack, VKA vitamin K antagonist
compared with apixaban plus clopidogrel plus placebo. Of
the ongoing trials, RT-AF is the only one that uses a lower
target INR (1.8–2.5). None of these trials are performing
a head-to-head comparison of different NOACs and there-
fore provide no insight into the difference in efficacy and
safety of these agents.
Discussion
All of the ongoing trials are primarily focused on the safety
endpoint in terms of major bleeding or clinically relevant
non-major bleeding. All of these trials are underpowered
to draw firm conclusions about the efficacy for stroke pre-
vention in AF. This is of importance, since some of the
trials (i.e. PIONEER AF-PCI and RT-AF) use a suboptimal
NOAC dose for stroke prevention in AF. The short follow-
up period of all the studies limits their ability to assess
the effect on stroke and venous thromboembolic events, es-
pecially in the long term. Furthermore, these studies are
also underpowered for the clinical endpoints death, my-
ocardial infarction and in-stent thrombosis in patients with
ACS. Most of the studies do not include patients who have
had a stroke or bleeding, although these events do not con-
traindicate NOAC use. When determining the optimal treat-
ment for an individual patient, the clinician should always
take into account bleeding risk factors. Modifiable bleeding
risk factors are, for example: adding a proton pump inhibitor
with DAPT to reduce the risk of gastrointestinal bleeding,
hypertension (<160mmHg target), alcohol use and the use
of predisposing co-medication such as non-steroidal anti-
inflammatory drugs.
Neth Heart J (2018) 26:334–340 339
Despite the efforts of researchers to synthesise more ev-
idence from the ongoing trials, there will still be challenges
for clinicians to choose the optimal treatment strategies for
individual patients on NOACs and (D)APT with AF under-
going PCI. The ESC guidelines and the AHA/ACC/HRS
recommendation to use the lowest effective NOAC dose in
combination with (D)APT in patients with AF and co-exist-
ing ACS or PCI were based on limited evidence concerning
the optimal combination of NOACs and APT (level of evi-
dence C; expert opinion) [3, 5, 8]. In this respect, the term
“lowest effective dose” could be confusing and the term
“lowest suitable dose for AF” would be more appropriate.
Current evidence indicates that the combination of NOAC
and clopidogrel is safer than VKA plus DAPT, which in-
creases the risk of bleeding, without clear advantages in
efficacy.
As to whether (N)OAC should be combined with single
APT rather than dual APT, evidence from the WOEST, PI-
ONEER AF-PCI and RE-DUAL PCI trials seems to favour
a combination with clopidogrel only, thus omitting aspirin
[21]. In this respect, a very interesting trial would involve
a treatment arm with only an OAC in an adequate dose
for stroke prevention in AF without APT. Unfortunately,
this has not been incorporated into any of the studies. A
direct comparison of clopidogrel versus aspirin as APT af-
ter PCI has not been studied. Evidence from a randomised
controlled trial in patients with atherosclerotic vascular dis-
ease (manifested as either ischaemic stroke, myocardial in-
farction or symptomatic peripheral artery disease) showed
that clopidogrel was more effective than aspirin in reducing
the combined risk of ischaemic stroke/myocardial infarc-
tion and vascular death [22]. A nationwide registry study
confirmed that there was a marginally significant reduc-
tion of MI and coronary death with OAC plus clopidogrel
compared to triple therapy in AF patients after myocardial
infarction or PCI. This reduction was not significant for
OAC plus aspirin [23]. Also, OAC plus aspirin was asso-
ciated with a significantly increased risk of death from all
causes. The choice of clopidogrel over aspirin in ongoing
trials seems to be based mainly on the WOEST trial results.
None of the studies thus far has made a direct comparison
of a VKA plus single APT versus a NOAC plus single APT.
The upcoming results of the AUGUSTUS trial will there-
fore be interesting owing to its 2× 2 factorial design (see
Tab. 1). The reduced-dose NOACs should only be given if
the dose reduction is indicated according to the patients’
characteristics as listed in the drug labelling, irrespective of
the APT used. A reduced-dose NOAC in “healthy” patients,
with the exception of dabigatran 110mg q.d., has not been
shown to be effective for stroke prevention in AF. A com-
mon mistake is to give apixaban 2.5mg combined with
APT instead of the full dose. However, this would only
be appropriate in the presence of dose-reduction criteria
(creatinine clearance 10–30ml/min or two out of three fol-
lowing: serum creatinine ≥133µmol/l, body weight 60kg
and/or age ≥80 years). The recommendation of the 2017
ESC guideline on DAPT to consider rivaroxaban 15mg q.d.
instead of 20mg when combined with aspirin and/or clopi-
dogrel should therefore be followed with caution because
this dose has not been proved to be effective for stroke
prevention in patients with AF. Consequently, rivaroxaban
2.5mg is not an option for stroke prevention in ACS patients
with AF.
The majority of the above-mentioned NOAC trials are
still recruiting at present, and the results will become avail-
able in the coming years. For now, triple therapy has proved
to be too much in terms of safety outcomes. However, it can
be expected that guidelines will continue to change in the
near future, and what seems wise today may become obso-
lete tomorrow.
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